A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel

Assay and Drug Development Technologies

Volumn 8, Issue 6, 2010, Pages 714-726

  Schmalhofer, William A ^a,b   Swensen, Andrew M ^a,c   Thomas, Brande S ^a   Felix, John P ^a,d   Haedo, Rodolfo J ^a,e   Solly, Kelli ^a   Kiss, Laszlo ^a   Kaczorowski, Gregory J ^a,f   Garcia, Maria L ^a,f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GlycoFi   (United States)

^c ABBOTT LABORATORIES   (United States)

^d PURDUE PHARMA L P   (United States)

^e NANION TECHNOLOGIES GMBH   (Germany)

^f Kanalis Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ASTEMIZOLE; CISAPRIDE; HALOPERIDOL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG INHIBITOR; RISPERIDONE; SOTALOL; TERFENADINE; THALLIUM; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; AUTOMATION; CHANNEL GATING; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; ELECTROPHYSIOLOGY; FUNCTIONAL THALLIUM FLUX ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOASSAY; IN VITRO STUDY; PATCH CLAMP; PHARMACOLOGICAL PARAMETERS;

ACTION POTENTIALS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; THALLIUM;

EID: 78650496072     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0351     Document Type: Article

References (24)

1. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
2. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
4. Huang FD, Chen J, Lin M, Keating MT, Sanguinetti MC: Long-QT syndrome-associated missense mutations in the pore helix of the HERG potassium channel. Circulation 2001;104:1071-1075.
5. Sanguinetti MC, Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-469.
6. Fermini B, Fossa AA: The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003;2:439-447.
7. Priest BT, Swensen AM, McManus OB: Automated electrophysiology in drug discovery. Curr Pharm Des 2007;13:2325-2337.
8. Priest BT, Bell IM, Garcia ML: Role of hERG potassium channel assays in drug development. Channels (Austin) 2008;2:87-93.
9. Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T: Characterization of a hERG screen using the lonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol 2005;3:47-57.
10. Beacham DW, Blackmer T, O'Grady M, Hanson GT: Cell-based potassium ion channel screening using the FluxOR assay. J Biomol Screen 2010;15:441-446.
11. Titus SA, Beacham D, Shahane SA, et al.: A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal Biochem 2009;394:30-38.
12. Weaver CD, Harden D, DworetzkySI, Robertson B, Knox RJ: A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J Biomol Screen 2004;9:671-677.
13. Bridal TR, Margulis M, Wang X, Donio M, Sorota S: Comparison of human ether-a-go-go-related gene screening assays based on lonWorks quattro and thallium flux. Assay Drug Dev Technol 2010;8:755-765.
14. Wang J, Della Penna K, Wang H, et al.: Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 2003;284:H256-H267.
15. Polak S, Wisniowska B, Brandys J: Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 2009;29:183-206.
16. Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM: Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 1998;82:386-395.
17. Mitcheson JS, Perry MD: Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Dev 2003;6:667-674.
18. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC: Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 2002;277:23587-23595.
19. Murphy SM, Palmer M, Poole MF, et al.: Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J Pharmacol Toxicol Methods 2006;54:42-55.
20. Piper DR, Duff SR, Eliason HC, et al.: Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach. Assay Drug Dev Technol 2008;6:213-223.
21. Jones KA, Garbati N, Zhang H, Large CH: Automated patch clamping using the QPatch. Methods Mol Biol 2009;565:209-223.
22. Kiss L, Bennett PB, Uebele VN, et al.: High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 2003;1(1 Pt 2):127-135.
23. Tao H, Santa Ana D, Guia A, et al.: Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol 2004;2:497-506.
24. Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G: A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 2002;3:455-459.